Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $2.6 million.

  • InMed Pharmaceuticals' Non-Current Assets fell 1959.35% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 1441.74%. This contributed to the annual value of $2.7 million for FY2025, which is 1341.88% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Non-Current Assets stood at $2.6 million, which was down 1959.35% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Non-Current Assets ranged from a high of $6.9 million in Q4 2021 and a low of $1.4 million during Q3 2021
  • Moreover, its 5-year median value for Non-Current Assets was $3.0 million (2024), whereas its average is $3.3 million.
  • The largest annual percentage gain for InMed Pharmaceuticals' Non-Current Assets in the last 5 years was 12513.35% (2022), contrasted with its biggest fall of 5781.2% (2022).
  • InMed Pharmaceuticals' Non-Current Assets (Quarter) stood at $6.9 million in 2021, then crashed by 57.81% to $2.9 million in 2022, then increased by 18.73% to $3.4 million in 2023, then dropped by 11.99% to $3.0 million in 2024, then dropped by 15.54% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.7 million for Q2 2025, and $2.9 million during Q1 2025.